NCT00920855 · OUTCOME

Kaplan-Meier Estimate for Overall Survival (OS)

Study of Bendamustine Combined With Bortezomib for Patients With Relapsed/Refractory Multiple Myeloma · Source last updated 2012-10-04

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: MEDIAN
Unit: months
Interval / dispersion: 95% Confidence Interval
Time frame: up to 23 months

What was measured

Overall survival is defined as the time from initiation of therapy to death from any cause or last follow-up visit.

Analysis population: Safety population

Groups in this outcome

Bendamustine and Bortezomib - Overall

Bendamustine in escalating doses of 50, 70 or 90 mg/m\^2 as combination therapy with bortezomib at 1.0 mg/m\^2/dose administered for up to eight 28 day cycles. Participants whose disease has not progressed at the end of the eight cycles will be followed until disease progression or death.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Bendamustine and Bortezomib - Overall	40

Reported measurements

Source class 1

Values in months · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Bendamustine and Bortezomib - Overall	17.82	Not reported	15.83	NA	Upper boundary was not estimated due to the limited number of participants with events.

Complete source fields

classes

categories
measurements
comment
Upper boundary was not estimated due to the limited number of participants with events.
group Id
OG000
lower Limit
15.83
upper Limit
NA
value
17.82

denoms

counts
group Id
OG000
value
40
units
Participants

description

Overall survival is defined as the time from initiation of therapy to death from any cause or last follow-up visit.

dispersion Type

95% Confidence Interval

groups

description
Bendamustine in escalating doses of 50, 70 or 90 mg/m\^2 as combination therapy with bortezomib at 1.0 mg/m\^2/dose administered for up to eight 28 day cycles. Participants whose disease has not progressed at the end of the eight cycles will be followed until disease progression or death.
id
OG000
title
Bendamustine and Bortezomib - Overall

param Type

MEDIAN

population Description

Safety population

reporting Status

POSTED

time Frame

up to 23 months

title

Kaplan-Meier Estimate for Overall Survival (OS)

type

SECONDARY

unit Of Measure

months

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice